Qiagen N.V. (QGEN)
|Net Income (ttm)||479.87M|
|Day's Range||53.63 - 54.24|
|52-Week Range||45.33 - 59.00|
|Price Target||56.67 (+5.0%)|
|Est. Earnings Date||Oct 26, 2021|
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate... [Read more...]
Financial PerformanceFinancial Statements
According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 56.67, which is an increase of 4.96% from the latest price.
MANCHESTER, England & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #manchester--QIAGEN strengthens UK footprint with move to new Manchester facilities
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q3 2021 and first nine months of 2021
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #qiareach--QIAGEN launches novel QIAreach QuantiFERON-TB tuberculosis test for high-burden regions
Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.
New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.
QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.
Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems. Related Link: Qiagen's COVID-19...
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN receives U.S. Department of Defense contract to further expand production capacity for NeuMoDx.
QGEN vs. ILMN: Which Stock Is the Better Value Option?
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #dax--QIAGEN to enter the DAX – Germany's leading stock market index
QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #billions--QIAGEN reaches milestone with its kits used to process more than three billion biological samples to date
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Di...
HILDEN, Germany & GERMANTOWN, Md. & FORT COLLINS, Colo.--(BUSINESS WIRE)---- $QGEN #COVID--QIAGEN and GT Molecular collaborate to offer a complete SARS-CoV-2 wastewater detection solution based on QIAcu...
Qiagen NV (NYSE: QGEN) and OncXerna Therapeutics have signed a master agreement to develop a next-generation sequencing (NGS) companion diagnostic for navicixizumab, which OncXerna is developing for ova...
HILDEN, Germany & WALTHAM, Mass. & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #cdx--QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.
The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE: QGEN) QIAreach SARS CoV-2 Antigen Test.
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hou...
GERMANTOWN, Maryland & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 a...
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.